Studies Yield Mixed Findings for Investigational Drug Abicipar in Wet AMD
05/05/2020
The investigational drug abicipar pegol is noninferior to ranibizumab for achieving stable vision in people with wet age-related macular degeneration (AMD), according to a pair of phase-3 trials, as reported by Reuters.wet
Abicipar requires less-frequent administration, but the trials show it has more side effects than ranibizumab, and its potential role in wet AMD treatment is unclear, experts say. The drug, from Allergan and Molecular Partners AG, belongs to a new class of therapeutics called DARPins, or designed ankyrin repeat proteins.